DNAbilize Licensing Bio-Path markets DNAbilize, a liposomal antisense delivery technology with broad systemic reach and favorable safety profile, presenting a licensing opportunity for collaborators seeking efficient nucleic acid drug delivery beyond liver-targeted therapies.

Lead Program Strength Lead candidate BP1001 has completed safety segments in AML Phase II and planned CML Phase II, indicating nearing clinical validation and potential for co-development or licensing with oncology partners seeking novel leukemia treatments.

Early Stage Portfolio A second liposomal antisense candidate poised for lymphoma and solid tumors, plus BP1001-A for obesity/metabolic diseases, suggests multiple collaboration lanes across cancer and metabolic indications for partner-initiated programs.

Strategic Advisory Recently added Scientific Advisory Board members signal ongoing scientific momentum and credibility, which can facilitate discussions with potential pharma partners about joint development and external funding opportunities.

Financial Signals Publicly traded with modest revenue in the 1–10 million range and recent financing activity, Bio-Path may be receptive to partnerships that de-risk programs, co-development deals, or strategic investments to accelerate clinical milestones.